ASP4058 (100 nM) significantly reduced FITC-dextran leakage through an endothelial monolayer and suppressed the migration of macrophages across the monolayer in vitro by using a Transwell system.[2]

ASP4058 (0.1 and 0.3 mg/kg; p.o.; daily for day 12 to day 45) maintains the clinical score at a relatively low level and the cumulative clinical scores (18-45 dpi) among the groups treated with 0.1 and 0.3 mg/kg dosages are 6.90±2.85 and 5.60±2.21, respectively in mice. The ED50 value for ASP4058 is 0.063 mg/kg.[1]
ASP4058 (0.03, 0.1, and 0.3 mg/kg; p.o., daily for 21 days) reduces the clinical score in a dose-dependent manner and the cumulative clinical score from day 0 to 21 dpi at 0.03, 0.1, and 0.3 mg/kg are 15.5±1.48, 9.50±2.17 and 1.17±1.17, respectively, while that of the vehicle-treated group is 15.5±0.619 in rats.[1]